1,102 results

#34912-AAV5

Ready-to-use AAV5 particles produced from paavCAG-post-mGRASP-2A-dTomato (#34912). In addition to the viral particles, you will also receive purified paavCAG-post-mGRASP-2A-dTomato plasmid DNA. CAG-driven expression of post-synaptic mGRASP-2A-dTomato for synaptic connectivity mapping. These AAV preparations are suitable purity for injection into animals.

Jinhyun Kim

Kim et al Nat Methods. 2011 Dec 4;9(1):96-102. doi

Aug. 7, 2025

Academic Institutions and Nonprofits only

#34910-AAV5

Ready-to-use AAV5 particles produced from paavCAG-pre-mGRASP-mCerulean (#34910). In addition to the viral particles, you will also receive purified paavCAG-pre-mGRASP-mCerulean plasmid DNA. CAG-driven expression of presynaptic mGRASP-mCerulean for synaptic connectivity mapping. These AAV preparations are suitable purity for injection into animals.

Jinhyun Kim

Kim et al Nat Methods. 2011 Dec 4;9(1):96-102. doi

Aug. 7, 2025

Academic Institutions and Nonprofits only

#98930-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 (#98930). In addition to the viral particles, you will also receive purified pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 plasmid DNA. GFAP-driven glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 27, 2018

Academic Institutions and Nonprofits only

#105715-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s (#105715). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s plasmid DNA. EF1a-driven, Cre-dependent GCaMP6s fused to the presynaptic protein synaptophysin. These AAV preparations are suitable purity for injection into animals.

Rylan Larsen

Oct. 20, 2020

Academic Institutions and Nonprofits only

#105557-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.CB7.CI.mCerulean.WPRE.RBG (#105557). In addition to the viral particles, you will also receive purified pENN.AAV.CB7.CI.mCerulean.WPRE.RBG plasmid DNA. CB7-driven mCerulean expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 25, 2018

Academic Institutions and Nonprofits only

#26968-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 21, 2018

Academic Institutions and Nonprofits only

#135631-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-GFP-fGFP (#135631). In addition to the viral particles, you will also receive purified pAAV-S5E2-GFP-fGFP plasmid DNA. Bicistronic expression of GFP and membrane-targeted GFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 15, 2021

Academic Institutions and Nonprofits only

#55645-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent Channelrhodopsin-EYFP expression for optogenetic activation. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Dec. 5, 2017

Academic Institutions and Nonprofits only

#112164-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn-FLEX.iGABASnFR.F102G (#112164). In addition to the viral particles, you will also receive purified pAAV.hSyn-FLEX.iGABASnFR.F102G plasmid DNA. Synapsin-driven, Cre-dependent iGABASnFR.F102G GABA sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2019 Aug;16(8):763-770. doi

Jan. 3, 2019

Academic Institutions and Nonprofits only

#214857-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14361: pAAV-AiE0452h_3xC2-minBG-jGCaMP8s-WPRE3-BGHpA (Alias: CN4361) (#214857). In addition to the viral particles, you will also receive purified AiP14361: pAAV-AiE0452h_3xC2-minBG-jGCaMP8s-WPRE3-BGHpA (Alias: CN4361) plasmid DNA. minBG-driven expression of jGCaMP8s in striatal indirect pathway medium spiny neurons (D2 MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Jan. 27, 2025

Academic Institutions and Nonprofits only

#83896-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hDlx-GiDREADD-dTomato-Fishell-5 (#83896). In addition to the viral particles, you will also receive purified pAAV-hDlx-GiDREADD-dTomato-Fishell-5 plasmid DNA. hDlx-driven expression of Gi-DREADD and nuclear localized dTomato (physically separate). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

June 1, 2020

Academic Institutions and Nonprofits only

#104491-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-syn-FLEX-jGCaMP7s-WPRE (#104491). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7s-WPRE plasmid DNA. Synapsin-driven, Cre-dependent, GCaMP7s calcium sensor. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

June 14, 2018

Academic Institutions and Nonprofits only

#50972-AAV8

Ready-to-use AAV8 particles produced from AAV-SYP1-miniSOG-T2A-mCherry (#50972). In addition to the viral particles, you will also receive purified AAV-SYP1-miniSOG-T2A-mCherry plasmid DNA. Syn-driven, InSynC expression. These AAV preparations are suitable purity for injection into animals.

Roger Tsien

Lin et al Neuron. 2013 Jul 24;79(2):241-53. doi: 1

Sept. 22, 2025

Academic Institutions and Nonprofits only

#162382-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE (#162382). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of the ultrafast calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

Sept. 27, 2023

Academic Institutions and Nonprofits only

#115645-LVC

Ready-to-use Concentrated Lentiviral Prep particles produced from pSMAL-CellTag-V3 (#115645). In addition to the viral particles, you will also receive purified pSMAL-CellTag-V3 plasmid DNA. Ready-to-use lentiviral particles carrying version 3 of the CellTag barcoding library to combinatorially index cells for single-cell analysis of clonal dynamics.

Samantha Morris

Biddy et al Nature. 2018 Dec;564(7735):219-224. doi:

Oct. 29, 2019

Academic Institutions and Nonprofits only

#213856-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiVIPe4_ChR2_mCherry (#213856). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the VIP interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#169128-AAV1

Ready-to-use AAV1 particles produced from pAAV-DIO-EF1α-mKate2-PDE4D3-Cat (#169128). In addition to the viral particles, you will also receive purified pAAV-DIO-EF1α-mKate2-PDE4D3-Cat plasmid DNA. EF1a-driven, Cre-dependent expression of truncated PDE4D3 and mKate2. These AAV preparations are suitable purity for injection into animals.

Georg Nagel

Zhang et al Nature. 2021 Sep;597(7875):245-249. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#208717-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-GRAB_g5-HT3.0 (#208717). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_g5-HT3.0 plasmid DNA. Synapsin-driven expression of GRAB_g5-HT3.0 sensor. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Deng et al Nat Methods. 2024 Apr;21(4):692-702. doi

Aug. 7, 2025

Academic Institutions and Nonprofits only

#140555-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_DA-mut (#140555). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_DA-mut plasmid DNA. Synapsin-driven expression of control dopamine sensor GRAB_DA-mut (does not respond to DA). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#213917-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_GCaMP6f (#213917). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only